We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sponsors of multisite clinical trials should take greater advantage of their ability to use a single institutional review board, according to a draft policy that requires the practice for all NIH-supported domestic trial sites.